Ubretid
Based on 1 Customer Validation
Ubretid is a potent inhibitor of plasma cholinesterase. Ubretid therefore delays the hydrolysis of suxamethonium and prolongs its action, similar to the effects shown by other anticholinesterase agents, such as pyridostigmine and donepezil. Ubretid has the potential for the research of urinary retention prolongs the effect of suxamethonium. Ubretid is commonly prescribed for the research of myasthenia gravis and for difficulty in emptying the bladder.
For research use only. We do not sell to patients.
- Purity: 99.0%
- CAS No.: 15876-67-2
- Formula: C22H32Br2N4O4
- Molecular Weight:576.32
-
Storage:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Neuronal Signaling Compound Library
HY-L013
-
Covalent Screening Library
HY-L036
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Rare Diseases Drug Library
HY-L102
-
Heterocyclic Compound Library
HY-L138
-
Membrane Protein-targeted Compound Library
HY-L149
-
Multi-Target Compound Library
HY-L176
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Covalent Screening Library Plus
HY-L036P
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
Biological Activity
|
AChE 0.25 μM (IC50) |
BChE 0.27 μM (IC50) |
Ubretid inhibits AChE and BChE (IC50s are 0.25 μM and 0.27 μM), increases the level of acetylcholine, activates cholinergic neural pathways, thereby regulating neuronal excitability and synaptic transmission[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Wistar rats models[2]
-
Dosage:50-100 μg/kg
-
Administration:ip, single dose
-
Result:Increased the level of acetylcholine in the medial prefrontal cortex of rats.
Decreased the motor activity and induced cholinergic behaviors such as tremor, fasciculation, and tearing.
Chemical Information
-
CAS No. 15876-67-2
-
Appearance Solid
-
Molecular Weight 576.32
-
Formula C22H32Br2N4O4
-
Color White to light yellow
-
SMILES
O=C(N(C)CCCCCCN(C)C(OC1=C[N+](C)=CC=C1)=O)OC2=C[N+](C)=CC=C2.[Br-].[Br-]
-
Synonyms
Distigmine dibromide
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvent & Solubility
DMSO : 100 mg/mL (173.51 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (269 KB)
-
SDS (479 KB)
- English - EN (479 KB)
- Français - FR (479 KB)
- Deutsch - DE (479 KB)
- Norwegian - NO (479 KB)
- Español - ES (479 KB)
- Swedish - SV (479 KB)
- Italian - IT (479 KB)
- Portuguese - PT (479 KB)
-
Handling Instructions (2659 KB)
References
[1]. Isono S, et al. Ubretid (distigmine bromide) taken to treat urinary retention prolongs the effect of suxamethonium. J Anesth. 2008;22(3):337. [Content Brief]
[2]. Nakayama K, et al., Effect of distigmine bromide on the central cholinergic system. J Psychopharmacol. 2009 Mar;23(2):190-3. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.7351 mL | 8.6757 mL | 17.3515 mL | 43.3787 mL |
| 5 mM | 0.3470 mL | 1.7351 mL | 3.4703 mL | 8.6757 mL | |
| 10 mM | 0.1735 mL | 0.8676 mL | 1.7351 mL | 4.3379 mL | |
| 15 mM | 0.1157 mL | 0.5784 mL | 1.1568 mL | 2.8919 mL | |
| 20 mM | 0.0868 mL | 0.4338 mL | 0.8676 mL | 2.1689 mL | |
| 25 mM | 0.0694 mL | 0.3470 mL | 0.6941 mL | 1.7351 mL | |
| 30 mM | 0.0578 mL | 0.2892 mL | 0.5784 mL | 1.4460 mL | |
| 40 mM | 0.0434 mL | 0.2169 mL | 0.4338 mL | 1.0845 mL | |
| 50 mM | 0.0347 mL | 0.1735 mL | 0.3470 mL | 0.8676 mL | |
| 60 mM | 0.0289 mL | 0.1446 mL | 0.2892 mL | 0.7230 mL | |
| 80 mM | 0.0217 mL | 0.1084 mL | 0.2169 mL | 0.5422 mL | |
| 100 mM | 0.0174 mL | 0.0868 mL | 0.1735 mL | 0.4338 mL |
Powered by Bioz